# ROMEO (Rosuvastatin in Metabolic syndrOme)

> **NCT00395486** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 258 (actual)

## Conditions studied

- Metabolic Syndrome X

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00395486
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2011-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395486, "ROMEO (Rosuvastatin in Metabolic syndrOme)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00395486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*